Literature DB >> 7625792

Evaluation of water-soluble pneumocandin analogs L-733560, L-705589, and L-731373 with mouse models of disseminated aspergillosis, candidiasis, and cryptococcosis.

G K Abruzzo1, A M Flattery, C J Gill, L Kong, J G Smith, D Krupa, V B Pikounis, H Kropp, K Bartizal.   

Abstract

The activities of the water-soluble pneumocandin derivatives L-733560, L-705589, and L-731373 were evaluated in mouse models of disseminated aspergillosis, candidiasis, and cryptococcosis and were compared with those of commercially available antifungal agents. Pneumocandins are inhibitors of 1,3-beta-D-glucan synthesis. In the aspergillosis model, L-733560 and L-705589 significantly prolonged the survival of DBA/2N mice challenged intravenously with Aspergillus fumigatus conidia. L-733560 and L-705589 exhibited efficacies comparable to that of amphotericin B (AMB) with 90% effective doses of 0.48, 0.12, and 0.36 mg/kg of body weight, respectively. Two mouse models of disseminated candidiasis were used to evaluate these compounds. In both models, mice were challenged intravenously with Candida albicans. In a C. albicans survival model with DBA/2N and CD-1 mice, the efficacy of L-733560 was comparable to that of AMB, while L-731373 and L-705589 were somewhat less active. In a previously described C. albicans target organ kidney assay, the pneumocandin analogs and AMB at doses of > or = 0.09 mg/kg were effective in sterilizing kidneys, while fluconazole and ketoconazole were considerably less active and did not sterilize kidneys when they were used at concentrations of < or = 100 mg/kg. Although orally administered L-733560 showed activity in both candidiasis models, its efficacy was reduced compared with that of parenterally administered drug. In a disseminated cryptococcosis mouse model that measures the number of CFU of Cryptococcus neoformans per gram of brain and spleen, L-733560 at 10 mg/kg was ineffective in reducing the counts in organs, while AMB at 0.31 mg/kg sterilized the organs. These results indicate that the pneumocandins may be beneficial as potent parenterally administered therapeutic agents for disseminated aspergillosis and candidiasis.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7625792      PMCID: PMC162686          DOI: 10.1128/AAC.39.5.1077

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  10 in total

1.  Synthesis and antifungal activity of novel cationic pneumocandin B(o) derivatives.

Authors:  F A Bouffard; R A Zambias; J F Dropinski; J M Balkovec; M L Hammond; G K Abruzzo; K F Bartizal; J A Marrinan; M B Kurtz; D C McFadden
Journal:  J Med Chem       Date:  1994-01-21       Impact factor: 7.446

2.  Resistant fits for some commonly used logistic models with medical application.

Authors:  D Pregibon
Journal:  Biometrics       Date:  1982-06       Impact factor: 2.571

Review 3.  Amphotericin B: 30 years of clinical experience.

Authors:  H A Gallis; R H Drew; W W Pickard
Journal:  Rev Infect Dis       Date:  1990 Mar-Apr

4.  In vitro and in vivo anti-Candida activity and toxicology of LY121019.

Authors:  R S Gordee; D J Zeckner; L F Ellis; A L Thakkar; L C Howard
Journal:  J Antibiot (Tokyo)       Date:  1984-09       Impact factor: 2.649

5.  Increased antifungal activity of L-733,560, a water-soluble, semisynthetic pneumocandin, is due to enhanced inhibition of cell wall synthesis.

Authors:  M B Kurtz; C Douglas; J Marrinan; K Nollstadt; J Onishi; S Dreikorn; J Milligan; S Mandala; J Thompson; J M Balkovec
Journal:  Antimicrob Agents Chemother       Date:  1994-12       Impact factor: 5.191

Review 6.  Systemically administered antifungal agents. A review of their clinical pharmacology and therapeutic applications.

Authors:  C A Lyman; T J Walsh
Journal:  Drugs       Date:  1992-07       Impact factor: 9.546

7.  Use of DBA/2N mice in models of systemic candidiasis and pulmonary and systemic aspergillosis.

Authors:  R F Hector; E Yee; M S Collins
Journal:  Infect Immun       Date:  1990-05       Impact factor: 3.441

8.  Pneumocandins from Zalerion arboricola. IV. Biological evaluation of natural and semisynthetic pneumocandins for activity against Pneumocystis carinii and Candida species.

Authors:  D M Schmatz; G Abruzzo; M A Powles; D C McFadden; J M Balkovec; R M Black; K Nollstadt; K Bartizal
Journal:  J Antibiot (Tokyo)       Date:  1992-12       Impact factor: 2.649

9.  In vitro antifungal activities and in vivo efficacies of 1,3-beta-D-glucan synthesis inhibitors L-671,329, L-646,991, tetrahydroechinocandin B, and L-687,781, a papulacandin.

Authors:  K Bartizal; G Abruzzo; C Trainor; D Krupa; K Nollstadt; D Schmatz; R Schwartz; M Hammond; J Balkovec; F Vanmiddlesworth
Journal:  Antimicrob Agents Chemother       Date:  1992-08       Impact factor: 5.191

10.  In vitro evaluation of the pneumocandin antifungal agent L-733560, a new water-soluble hybrid of L-705589 and L-731373.

Authors:  K Bartizal; T Scott; G K Abruzzo; C J Gill; C Pacholok; L Lynch; H Kropp
Journal:  Antimicrob Agents Chemother       Date:  1995-05       Impact factor: 5.191

  10 in total
  23 in total

1.  Geranylgeranyltransferase I of Candida albicans: null mutants or enzyme inhibitors produce unexpected phenotypes.

Authors:  R Kelly; D Card; E Register; P Mazur; T Kelly; K I Tanaka; J Onishi; J M Williamson; H Fan; T Satoh; M Kurtz
Journal:  J Bacteriol       Date:  2000-02       Impact factor: 3.490

Review 2.  Antifungal peptides: novel therapeutic compounds against emerging pathogens.

Authors:  A J De Lucca; T J Walsh
Journal:  Antimicrob Agents Chemother       Date:  1999-01       Impact factor: 5.191

Review 3.  Key issues concerning fungistatic versus fungicidal drugs.

Authors:  J R Graybill; D S Burgess; T C Hardin
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1997-01       Impact factor: 3.267

Review 4.  Clinical pharmacokinetics of inhaled antimicrobials.

Authors:  Chris Stockmann; Jessica K Roberts; Venkata K Yellepeddi; Catherine M T Sherwin
Journal:  Clin Pharmacokinet       Date:  2015-05       Impact factor: 6.447

5.  In vitro activities of semisynthetic pneumocandin L-733,560 against fluconazole-resistant and -susceptible Candida albicans isolates.

Authors:  J V Martinez-Suarez; J L Rodriguez-Tudela
Journal:  Antimicrob Agents Chemother       Date:  1996-05       Impact factor: 5.191

6.  Treatment of murine Candida krusei or Candida glabrata infection with L-743,872.

Authors:  J R Graybill; R Bocanegra; M Luther; A Fothergill; M J Rinaldi
Journal:  Antimicrob Agents Chemother       Date:  1997-09       Impact factor: 5.191

7.  Comparison of the echinocandin caspofungin with amphotericin B for treatment of histoplasmosis following pulmonary challenge in a murine model.

Authors:  S Kohler; L J Wheat; P Connolly; C Schnizlein-Bick; M Durkin; M Smedema; J Goldberg; E Brizendine
Journal:  Antimicrob Agents Chemother       Date:  2000-07       Impact factor: 5.191

8.  Identification of the FKS1 gene of Candida albicans as the essential target of 1,3-beta-D-glucan synthase inhibitors.

Authors:  C M Douglas; J A D'Ippolito; G J Shei; M Meinz; J Onishi; J A Marrinan; W Li; G K Abruzzo; A Flattery; K Bartizal; A Mitchell; M B Kurtz
Journal:  Antimicrob Agents Chemother       Date:  1997-11       Impact factor: 5.191

9.  Evaluation of the echinocandin antifungal MK-0991 (L-743,872): efficacies in mouse models of disseminated aspergillosis, candidiasis, and cryptococcosis.

Authors:  G K Abruzzo; A M Flattery; C J Gill; L Kong; J G Smith; V B Pikounis; J M Balkovec; A F Bouffard; J F Dropinski; H Rosen; H Kropp; K Bartizal
Journal:  Antimicrob Agents Chemother       Date:  1997-11       Impact factor: 5.191

10.  Creation, characterization and utilization of Cryptococcus neoformans mutants sensitive to micafungin.

Authors:  Akio Toh-E; Misako Ohkusu; Kiminori Shimizu; Masashi Yamaguchi; Naruhiko Ishiwada; Akira Watanabe; Katsuhiko Kamei
Journal:  Curr Genet       Date:  2017-05-30       Impact factor: 3.886

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.